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Abstract
Parathyroid gland disorders are rare conditions with an incidence that displays great vari-
ability among populations. Its direct influence in calcium homeostasis originates variable
symptoms that affect bone remodelling among other processes. This study aimed to provide
data on the epidemiology and characteristics of patients admitted with these disorders in
Spain between 2003 and 2017, and to analyse disease management and direct medical
costs. Medical records in which a disorder of the parathyroid gland was registered as the
admission motive were extracted from a nationwide hospital-discharge database via the
Spanish Ministry of Health. Records from 12,903 patients were obtained, with predomi-
nance of female patients (74.70%) and of admissions due to hyperparathyroidism (90.23%).
The number of patients admitted per year increased over the study period along the inci-
dence of these disorders. The year 2017 incidence of hyperparathyroidism was 2.95 per
10,000, 4.03 per 10,000 in females and 1.37 in males; the same year, the incidence of hypo-
parathyroidism was 0.17 per 10,000. Length of hospital stay was significantly extended in
patients with hypoparathyroidism (7.16 days), admitted mostly due to emergencies. Heart
failure was diagnosed in more than 20% of admissions in patients with secondary and ter-
tiary hyperparathyroidism and hypoparathyroidism, while this last group displayed the high-
est levels of mineral metabolism disruption. Parathyroidectomy was performed in 78.95% of
all admissions for primary hyperparathyroidism. The total annual direct medical cost para-
thyroid gland disorders has increased over the study period, due to the increase of the costs
associated to hyperparathyroidism, whereas the cost per patient remained relatively stable,
with an average of €3,748, €3,430 and €3,737 for patients with hyperparathyroidism, hypo-
parathyroidism and other disorders of the parathyroid gland, respectively. This study pro-
vides novel data to extend the scarce available knowledge on parathyroid gland disorders’
epidemiology and management in Spain.
Introduction
The disorders of the parathyroid glands are heterogeneous rare conditions generally characterised
by the misregulation of calcium homeostasis due alterations in the secretion of parathormone
PLOS ONE
PLOS ONE | https://doi.org/10.1371/journal.pone.0230130 March 10, 2020 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Darbà J, Marsà A (2020) Epidemiology
and management of parathyroid gland disorders in
Spain over 15 years: A retrospective multicentre
analysis. PLoS ONE 15(3): e0230130. https://doi.
org/10.1371/journal.pone.0230130
Editor: Ana Paula Arez, Universidade Nova de
Lisboa Instituto de Higiene e Medicina Tropical,
PORTUGAL
Received: December 20, 2019
Accepted: February 21, 2020
Published: March 10, 2020
Copyright: © 2020 Darbà, Marsà. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data are available
upon request to the Spanish Ministry of Health for
any interested researcher, yet data sharing is
restricted due to legal stipulations. Requests must
be addressed to the Unit of Health Care Information
and Statistics (Spanish Institute of Health
Information) https://www.mscbs.gob.es/
estadEstudios/sanidadDatos/home.htm
Funding: BCN Health Economics & Outcomes
Research SL provided support in the form of
salaries for the author AM, but did not have any
(PTH), which, in normal conditions, regulates serum calcium levels [1,2]. Primary hyperparathy-
roidism (hyperPT) is the most common of these disorders, defined by the finding of hypercalcae-
mia alongside an increased serum PTH concentration [3]. Its incidence appears to correlate with
age, with the highest rates found after the 55 years of age, and it is 3–4 times more frequent in
females than in males [4,5]. Its overall incidence displays great variability within populations, vari-
ous studies worldwide estimate annual incidence rates of around 2–4 per 10,000 individuals,
although other estimations have reached the 80–90 per 10,000, in all cases with great fluctuations
over time [5–7]. The diagnosis of asymptomatic patients via serum calcium screening is not rare;
yet, the principal symptoms of hyperPT arise from the hypercalcaemia and may include fatigue,
mild depression, polyuria and augmented bone remodelling with an increased risk of fracture
[8,9]. In terms of management, when present, life-threatening hypercalcaemia is treated; subse-
quently, symptomatic patients are generally subjected to parathyroidectomy [9]. For asymptom-
atic patients, specific guidelines must be consulted. Secondary hyperPT, frequently derived from
chronic kidney disease (CKD), and tertiary hyperPT, that follows long-standing secondary
hyperPT with hypercalcaemia, are rarer parathyroid gland disorders presenting symptoms of
bone, organic and metabolic disorders [10,11]. These forms are primarily pharmacologically
treated and may occasionally require parathyroid surgery [10,12].
On the other hand, hypoparathyroidism (hypoPT) is a less common parathyroid gland dis-
order, characterised by low calcium levels in the blood serum due to inadequately low parathy-
roid hormone (PTH) levels [13]. Its incidence is around 1–3 per 10,000 and it is in most cases
associated to a previous intervention to the neck, including total thyroidectomy [14–16]. Its
symptoms result from the underlying hypocalcaemia causing increased neuromuscular irrita-
bility and typically appear along an increased bone mineral density and reduced bone remod-
elling, all pharmacologically treated [15,17].
The scarce and variable existent epidemiologic data for parathyroid gland disorders repre-
sents a major limitation that hampers the analysis of the management and costs of these disor-
ders, and the use of real-world data for the development of management and treatment
guidelines. This study aimed to provide data on the characteristics of patients admitted with
parathyroid gland disorders in secondary care centres in Spain, along with an analysis of dis-
ease incidence, management and direct medical costs in the country.
Methods
Data extraction
Admission records corresponding to patients admitted with a parathyroid gland disorder in
secondary healthcare centres (hospitals and specialised care centres) in Spain between 2003
and 2017 were obtained from the Spanish discharge database for Hospitalisation and Special-
ised Care via the Spanish Ministry of Health.
The dataset is codified using the 9th revision of the International Statistical Classification of
Diseases and Related Health Problems (ICD9) until 2015 and the 10th revision (ICD10) after
2016. The records of patients with a parathyroid gland disorder registered as the admission
motive were identified using the codes: 252.xx, E20.x and E21.x. The codes to identify the dif-
ferent classes of hyperPT were introduced in 2006. Extraction criteria claimed 13,897 files that
corresponded to 12,903 single patients.
Files did not contain any parameters identifying healthcare centres and medical history,
which are re-coded within the database maintaining records anonymised, in accordance with
the principles of Good Clinical Practice and the Declaration of Helsinki. This research did not
involve human participants and there was no access to identifying information; in this context
the Spanish legislation does not require patient consent and ethics committee approval [18].
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Data analysis
The first admission per patient registered during the study period was used for patient classifi-
cation and description. The direct medical costs of secondary care were calculated based on
the standardised average expenses of admissions and medical procedures determined by the
Spanish Ministry of Health, including all expenses related to the admission (examination,
medication, surgery, costs associated to personnel, medical equipment and resources) and
excluding the costs of prescription medication.
Descriptive values are presented using mean and standard deviation (SD) or data range.
Incidence was estimated as the proportion of patients admitted with parathyroid gland disor-
ders within the database, excluding the groups with an insufficient annual patient number to
preserve data reliability. Odds ratio (OR) with 95% confidence interval (CI) were used to eval-
uate associations in the diagnosis of comorbidities as indicated. Two-tailed T-student or one-
way analysis of variance were used as appropriate, with a p<0.05 considered statistically signif-
icant. Statistical analyses were performed using Microsoft Excel© Professional Plus 2010
(Microsoft Corporation, Redmond, WA, USA).
Results
Between 2003 and 2017, 13,897 admissions, corresponding to 12,903 patients, were registered
in the database with a disorder of the parathyroid gland registered as an admission motive.
Most of the patients included in the study were admitted due to hyperparathyroidism
(90.23%), and female patients were predominant across all groups (Table 1). Due to the late
introduction of the codes corresponding to primary, secondary and tertiary hyperPT, a large
number of patients were registered with an unspecified type of hyperPT.
The annual number of single-patients admitted with hyperparathyroidism in healthcare
centres in Spain increased over the study period (Fig 1A). Interestingly, patients’ mean age at
admission increased over the years, from 59.02 years in 2003 to 61.07 years in 2017 in the
group of patients with hyperPT (p<0.001), and remained stable in the group of patients with
hypoPT.
The incidence of hyperparathyroidism was 2.33 per 10,000 individuals as calculated during
the study period, whereas the incidence of hypoparathyroidism was 0.20 per 10,000 (Fig 1B).
The year 2017 incidence of hyperPT was 2.95 per 10,000, 4.03 per 10,000 in females and 1.37
in males; the same year, the incidence of hypoPT was 0.17 per 10,000.
The vast majority of admissions due to hyperPT were scheduled (86.34%), whereas 85.69%
of the admissions registered due to hypoPT were urgent and non-scheduled. Only 37 (0.27%)
Table 1. Characteristics of patients admitted with disorders of the parathyroid gland in hospitals and specialised care centres.
Patient characteristics Admissions Patients % females Age (SD)
Disorders of the parathyroid gland 13,897 12,903 74.70 59.03 (15.58)
Hyperparathyroidism 12,539 11,667 74.05 59.70 (14.70)
Primary 8,080 7,518 72.17 59.98 (14.58)
Secondary 175 155 75.48 59.39 (17.87)
Tertiary 226 201 79.10 53.99 (15.09)
Unspecified 4,058 3,793 77.43 59.47 (14.87)
Hypoparathyroidism 1,069 955 82.72 52.72 (21.87)
Other specified disorders of the parathyroid gland a 230 224 74.11 52.01 (18.71)
Unspecified disorder of the parathyroid gland 59 57 75.44 54.96 (19.29)
a Haemorrhage of the parathyroid gland or cyst of the parathyroid gland.
https://doi.org/10.1371/journal.pone.0230130.t001
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of all registered admissions were outpatient admissions, 34 due to hyperPT. Mean length of
hospital stay (LOHS) was 4.57 days (0–144) for patients with hyperPT, and significantly pro-
longed in patients with hypoPT, averaging 7.16 days (0–72) (p<0.001). In addition, this
parameter was found to decrease significantly over time from 6.19 days and 7.80 days in 2003
to 3.35 days and 6.50 days in 2017 for admissions due to hyperPT and hypoPT, respectively
(p<0.001) (Fig 2A).
Patients with hyperPT were predominantly discharged by General Surgery services and
those admitted with hypoPT were discharged by Internal Medicine and Endocrinology ser-
vices (Fig 2B).
Secondary conditions registered on admission were analysed per subgroups of patients
(Table 2). Various conditions were more frequently diagnosed in patients with hyperPT versus
those with hypoPT, indicating the distinctive nature of these disorders, as essential hyperten-
sion (OR = 1.40, 95%CI 1.22–1.61), benign neoplasms of the parathyroid gland (OR = 30.71,
95%CI 12.74–74.03) and osteoporosis (OR = 5.09, 95%CI 3.29–7.87).
The type of admission was associated with specific conditions; particularly, urgent admis-
sions were associated with disorders of mineral metabolism (OR = 4.16, 95%CI 3.80–4.57),
heart failure (OR = 1.81, 95%CI 1.63–2.00) and anaemia (OR = 3.11, 95%CI 2.62–3.70).
The medical procedures registered during the admission were analysed separately, revealing
interesting information on patients’ condition and disease management (Table 3). In 69.11%
of all admissions for hyperPT a parathyroidectomy was performed. Diagnostic imaging tech-
niques were common in all patient groups, focusing on the parathyroid and thyroid glands
and the analysis of bone density.
In a follow-up analysis focused on patients admitted for primary hyperPT, solely 15.50% of
these patients were not subjected to parathyroidectomy during the study period. With a mean
age of 64.31 (SD = 16.45), these patients were older than those with primary hyperPT that
underwent parathyroid excision or resection (p<0.001), and diagnoses of hypercalcaemia
(OR = 3.03, 95%CI 2.60–3.55) and heart failure (OR = 2.05, 95%CI 1.75–2.42) were increased
in this group. In addition, 18.81% of these patients were subjected to a thyroidectomy.
In terms of healthcare costs, the total annual direct medical cost parathyroid gland disor-
ders has increased over the study period, due to the increase of the costs associated to hyperPT
(Fig 3A), whereas no clear trend was identified in the cost per patient, due to groups with a
small patient number and the big effects observed due to specific patients requiring intensive
Fig 1. (A) Single-patients admitted with hyperparathyroidism (hyperPT), hypoparathyroidism (hypoPT) and other parathyroid gland disorders and (B) incidence of
parathyroid gland disorders in Spain over time (2003–2017).
https://doi.org/10.1371/journal.pone.0230130.g001
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levels of care (Fig 3B). Nevertheless, data suggests a decrease in the cost per patient between
2011 and 2014.
The mean annual direct medical cost per patient with hyperPT was €3,748, €3,430 for those
with hypoPT, and the annual cost per patient in those admitted with other disorders of the
parathyroid gland was €3,737. Overall, the cost per admission increased significantly over the
years, from a mean of €2,869, €2,510 and €2,779 in 2003 to €3,726, €3,666 and €3,668 in 2017
for patients with hyper PT, hypoPT and other disorders of the parathyroid gland, respectively
(p<0.001).This cost was significantly higher in patients with hyperPT hospitalised for more
than 50 days, reaching the €7,176 (p<0.001).
Discussion
While few studies have explored the epidemiology and overall status of parathyroid gland dis-
orders in Spain, data indicates an increase of their incidence within the Spanish population.
Fig 2. (A) Length of hospital stay over time and (B) principal services registered at discharge in patients with hyperparathyroidism (hyperPT) and hypoparathyroidism
(hypoPT). GS, General Surgery; ORL, Otorhinolaryngology; IM, Internal Medicine; END, Endocrinology.
https://doi.org/10.1371/journal.pone.0230130.g002
Table 2. Secondary conditions registered in more than 10% of all admissions of patients with parathyroid gland disorders.
Secondary diagnoses associated to disorders of the
parathyroid gland
Admissions, %
Primary HyperPT
N = 8,080
Secondary HyperPT
N = 175
Tertiary HyperPT
N = 226
HypoPT
N = 1,069
Unspecified essential hypertension 33.66 26.29 34.96 23.57
Hypercholesterolaemia and hyperlipidaemia 18.99 20.57 26.55 16.09
Disorders of mineral metabolism 12.92 21.72 22.12 59.03
Hypercalcaemia 8.97 9.14 7.08 3.09
Hypocalcaemia 2.24 8.00 5.75 40.41
Magnesium 0.33 2.86 2.21 8.98
Benign neoplasm 21.18 18.86 7.96 2.53
Parathyroid gland 16.91 14.29 5.31 0.47
Heart failure 10.83 21.71 23.89 20.58
Atrial fibrillation 3.81 8.57 3.98 6.08
Diabetes 12.96 16.00 12.39 12.16
Osteoporosis 11.06 9.14 5.31 1.96
Hypertensive chronic kidney disease 3.95 15.43 16.81 4.40
Anaemia 3.04 12.00 7.52 10.01
https://doi.org/10.1371/journal.pone.0230130.t002
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Preliminary results obtained from a single centre in the north of Spain suggested an incidence
rate of primary hyperPT that rapidly increased over the years and reached the 2.14 per 10,000
females between 2010 and 2014 [19]. The incidence of parathyroid gland disorders established
Table 3. Medical procedures registered during the admission of patients with parathyroid gland disorders.
Medical procedures registered during the admission Admissions, %
Primary HyperPT
N = 8,080
Secondary HyperPT
N = 175
Tertiary HyperPT
N = 226
HypoPT
N = 1,069
Surgical and therapeutic procedures
Parathyroidectomy 78.95 51.94 70.21 2.44
Thyroidectomy 12.92 6.20 14.36 0.61
Thyroid and parathyroid tissue reimplantation 1.39 3.88 13.30 0.92
Thymectomy and other excision of thymus 1.19 3.38 5.32 0.00
Injection or infusion of a therapeutic substance 6.03 8.53 8.51 19.13
Injection or infusion of electrolytes 4.37 6.98 3.72 6.10
Hemodialysis 0.42 3.10 7.45 0.71
Diagnosis and imaging procedures
Diagnostic ultrasound 14.38 19.60 14.36 16.09
Head and neck 7.41 6.98 6.38 4.78
Biopsy of thyroid or parathyroid gland 6.06 3.88 5.32 0.92
Microscopic examination of blood 5.06 12.40 5.32 12.61
X-ray of various sites 4.89 17.05 4.79 12.72
Electrocardiogram 4.31 8.53 5.85 6.94
Parathyroid radioisotope scan 3.74 5.43 3.19 0.51
Thyroid scan and radioisotope function studies 3.32 4.65 2.13 0.20
Computerized axial tomography of head 3.16 6.20 3.19 11.29
Computerized axial tomography of abdomen 2.68 3.88 3.19 2.95
Computerized axial tomography of thorax 2.38 5.43 2.13 3.46
Bone radioisotope scan and density studies 2.04 4.65 1.06 1.02
Magnetic resonance imaging 1.38 5.43 2.66 4.07
Measurement of systemic arterial/venous blood gases 1.35 3.88 4.79 7.73
Microscopic examination of specimen from bladder and of
urine
1.11 5.43 4.79 3.87
https://doi.org/10.1371/journal.pone.0230130.t003
Fig 3. (A) Total annual direct medical cost of secondary care of parathyroid gland disorders (N = 12,903) and (B) annual direct medical cost per patient (2003–2017).
https://doi.org/10.1371/journal.pone.0230130.g003
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in the present study, based on the evaluation of data obtained for the whole country, is not dis-
tant from those figures. The incidence of hyperPT also increased between 2003 and 2017,
although data is not directly comparable. Similarly, estimations appear in line with measures
obtained in the United States [5–7,9]. Such increasing tendencies could be correlated to an
improvement in the diagnosis of these disorders.
Patients with parathyroid gland disorders admitted in hospitals and specialised care centres
in Spain were mostly females and principally diagnosed with hyperPT. Interestingly, mean age
was inferior in patients admitted with hypoPT (52.72 years) versus those with hyperPT (59.70
years). Further analysis described a group of patients that exhibited frequent diagnoses of
essential hypertension, similarly to what was observed in the total hospitalised population the
year 2015 (29.89%) [20]. In addition, in 16.91% of the admissions of patients with primary
hyperPT underlying benign parathyroid tumours were registered, a percentage that is rela-
tively low, as it was the diagnosis in-situ of hypercalcaemia. These conditions may not be regis-
tered in all of the admissions in previously diagnosed patients, in which clinicians may register
hyperPT only; additionally, previous diagnoses obtained in primary care centres cannot be dis-
carded. Contrarily, 40.41% of the patients with hypoPT were diagnosed with hypocalcaemia
upon admission. In fact, exacerbated symptoms of hyper and hypocalcaemia, anaemia and
heart failure were seemingly the reason for urgent admissions, registered principally in
patients with hypoPT.
The rarity of these disorders has complicated its management and the standardisation of
protocols. However, previous data indicates a slow implementation of international guidelines
in the country, specifically, the application of the recommendations from the Third Interna-
tional Workshop for the management of primary hyperPT [21,22]. Further analyses of guide-
line adherence are not available for Spain; yet, its application cannot be discarded. In 2012, a
consensus document was published by the Bone Metabolism Working Group of the Spanish
Society of Endocrinology for the evaluation and follow-up of patients with normocalcemic pri-
mary hyperPT [23]. In parallel, international Workshop guidelines were updated in 2014 with
recommendations to evaluate renal and skeletal involvement prior to parathyroid surgery in
patients with primary hyperPT, while maintain the recommended age under 50 years [24].
The most recent guidelines for the management and treatment of primary hyperPT have been
published by the National Institute for Health and Care Excellence of England and the PARAT
program focusing on parathyroid gland disorders established by The European Society of
Endocrinology [3,25]. Similarly, recommendations have been established for secondary and
tertiary hyperPT and hypoPT [10,17].
Data herein suggests general guideline adherence, although this cannot be evaluated in
detail. Diagnosis imaging techniques and blood examination were common in all patient
groups. Almost 80% of the patients that were diagnosed with primary hyperPT were subjected
to parathyroidectomy, leaving out a group of older patients with more frequent diagnoses of
heart failure. The injection or infusion in-hospital of a therapeutic substance was increased in
patients with hypoPT without further description.
On the other hand, internal Spanish dynamics may have influenced disease management.
The decrease measured in the LOHS, coincides with a general decrease in this parameter
described in the total hospitalised Spanish population over the past 20 years [20]. In addition,
the annual increase of total medical costs correlates with the increase measured in the number
of single patients admitted per year, with medical costs that only declined between 2011 and
2014, coinciding with a general decrease of hospitalisation costs in Spain due to budget adjust-
ments during the economic crisis [20]. Data suggests an effect in the cost per patient that could
not be measured directly due to the large variation measured among patients.
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Finally, reference measures for the medical cost of parathyroid gland disorders are scarce.
The year 2000, the estimated cost of minimally invasive parathyroidectomy for primary
hyperPT was approximately €5,900, whereas the estimated cost associated to hypoPT was
€5,036 in 2013, both measured in the United States [26,27]. Annual costs measured in the
present study would be in line with such calculations, and the average €3,748, €3,430 and
€3,737 estimated herein for patients with hyperPT, hypoPT and other disorders of the parathy-
roid gland, respectively, would represent a 2.3 fold increase on average versus the hospitalisa-
tion costs estimated for the total Spanish population [20].
Additional limitations may have influenced the results of this study. Only patients that have
been admitted in hospitals and specialised care centres (inpatient and outpatient) are included
in the study. This could introduce a bias, considering that, for some patients, diagnosis could
be achieved in primary care centres. In addition, the database providing this data is codified
with ICD9 and ICD10 codes, thus, data veracity is subjected to the accuracy of codification
achieved within care centres. The codes identifying primary and secondary hyperPT were not
fully used until 2006; its slow introduction and the large number of patients with an unspeci-
fied type of hyperPT impeded the estimation of incidence and any temporal analysis per each
hyperPT type. Future evaluations in Spain and other European countries will be required to
validate these results and to extend the analysis of parathyroid gland disorders epidemiology
to other countries.
Conclusions
Data describing the epidemiology and burden of disorders of the parathyroid gland is scarce,
which hampers the formulation of clinical guidelines based on real-world data. This study
describes patient profile, management and cost of these disorders in Spain, as well as its inci-
dence, that continues to increase. Despite the relevance of primary hyperPT, the development
and revision of management guidelines focusing on hypoPT patients appears necessary, con-
sidering the large percentage of patients requiring urgent care.
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